Versor Investments LP Takes $893,000 Position in Repligen Co. (NASDAQ:RGEN)

Versor Investments LP acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 6,001 shares of the biotechnology company's stock, valued at approximately $893,000.

Other institutional investors have also bought and sold shares of the company. Toronto Dominion Bank raised its position in shares of Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after buying an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale raised its holdings in Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock worth $982,000 after purchasing an additional 89 shares in the last quarter. Ballentine Partners LLC lifted its position in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock worth $269,000 after purchasing an additional 105 shares during the period. Diversified Trust Co boosted its stake in Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after purchasing an additional 106 shares in the last quarter. Finally, CWM LLC increased its position in shares of Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 114 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company's stock, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Benchmark restated a "hold" rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reissued an "outperform" rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective on the stock. UBS Group cut their target price on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, July 31st. Finally, Stephens restated an "overweight" rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Repligen has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.

Repligen Trading Up 1.3 %

Repligen stock traded up $1.88 during midday trading on Wednesday, reaching $150.47. The stock had a trading volume of 1,073,706 shares, compared to its average volume of 659,834. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm has a market cap of $8.43 billion, a price-to-earnings ratio of -406.66, a PEG ratio of 4.27 and a beta of 0.96. The firm's fifty day simple moving average is $141.59 and its two-hundred day simple moving average is $144.78.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. Repligen's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.23 earnings per share. Equities analysts anticipate that Repligen Co. will post 1.45 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.